Skip to main content

LCD L36021: MolDX: Molecular Diagnostic Tests (MDT)

LCD L36021, MolDX: Molecular Diagnostic Tests (MDT), is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2025-08-21 and first in force 2015-10-01. The policy text runs 630 words, and its billing and coding article A54188 lists 253 ICD-10-CM codes that support medical necessity for 1 procedure code. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 519 covered ICD-10-CM codes: 2 fewer codes than L35025 (Palmetto GBA, 521 codes, revised 2023-05-04) and 6 fewer codes than L36807 (Wisconsin Physicians Service Insurance Corporation, 525 codes, revised 2025-05-29).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2025-08-21
Original effective
2015-10-01
Policy text
630 words
Covered ICD-10 codes (articles)
519

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L36021
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding articles A54188, A54191, A54192 and 15 more: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A54188 (Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID®), Billing and Coding A54191 (Billing and Coding: MolDX: FDA-Approved BRAF Tests), Billing and Coding A54192 (Billing and Coding: MolDX: FDA-Approved EGFR Tests), Billing and Coding A54194 (Billing and Coding: MolDX: MammaPrint), Billing and Coding A54195 (Billing and Coding: MolDX: Oncotype DX® Breast Cancer Assay), Billing and Coding A54196 (Billing and Coding: MolDX: Oncotype DX® Colon Cancer Assay Update), Billing and Coding A54257 (Billing and Coding: MolDX: BluePrint® Test), Billing and Coding A54269 (Billing and Coding: MolDX: HTTLPR Gene Testing), Billing and Coding A54270 (Billing and Coding: MolDX: IKBKAP Genetic Testing), Billing and Coding A54283 (Billing and Coding: MolDX: SULT4A1 Genetic Testing), Billing and Coding A54295 (Billing and Coding: MolDX: PIK3CA Gene Tests), Billing and Coding A54300 (Billing and Coding: MolDx: SEPT9 Gene Test), Billing and Coding A54688 (Billing and Coding: MolDX: FDA-Approved KRAS Tests), Billing and Coding A54830 (Billing and Coding: MolDX: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268)), Billing and Coding A55716 (Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)), Billing and Coding A56106 (Billing and Coding: MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors), Billing and Coding A56973 (Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT)), Billing and Coding A59646 (Billing and Coding: MolDX: Proteomics Testing) carry the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A54188: Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID® (Billing and Coding, effective 2024-10-01)

Covered ICD-10-CM codes
253
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A54188
ICD-10-CMDescription (FY2027)
C02.1Malignant neoplasm of border of tongue
C08.9Malignant neoplasm of major salivary gland, unspecified
C09.9Malignant neoplasm of tonsil, unspecified
C11.8Malignant neoplasm of overlapping sites of nasopharynx
C15.3Malignant neoplasm of upper third of esophagus
C15.4Malignant neoplasm of middle third of esophagus
C15.5Malignant neoplasm of lower third of esophagus
C15.9Malignant neoplasm of esophagus, unspecified
C16.0Malignant neoplasm of cardia
C16.2Malignant neoplasm of body of stomach
C16.8Malignant neoplasm of overlapping sites of stomach
C16.9Malignant neoplasm of stomach, unspecified
C17.9Malignant neoplasm of small intestine, unspecified
C18.0Malignant neoplasm of cecum
C18.2Malignant neoplasm of ascending colon
C18.4Malignant neoplasm of transverse colon
C18.7Malignant neoplasm of sigmoid colon
C18.8Malignant neoplasm of overlapping sites of colon
C18.9Malignant neoplasm of colon, unspecified
C22.0Liver cell carcinoma
C22.1Intrahepatic bile duct carcinoma
C22.7Other specified carcinomas of liver
C22.8Malignant neoplasm of liver, primary, unspecified as to type
C22.9Malignant neoplasm of liver, not specified as primary or secondary

Procedure codes: 81540.

A54191: Billing and Coding: MolDX: FDA-Approved BRAF Tests (Billing and Coding, effective 2023-11-16)

Covered ICD-10-CM codes
56
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A54191
ICD-10-CMDescription (FY2027)
C18.0Malignant neoplasm of cecum
C18.1Malignant neoplasm of appendix
C18.2Malignant neoplasm of ascending colon
C18.3Malignant neoplasm of hepatic flexure
C18.4Malignant neoplasm of transverse colon
C18.5Malignant neoplasm of splenic flexure
C18.6Malignant neoplasm of descending colon
C18.7Malignant neoplasm of sigmoid colon
C18.8Malignant neoplasm of overlapping sites of colon
C18.9Malignant neoplasm of colon, unspecified
C19Malignant neoplasm of rectosigmoid junction
C20Malignant neoplasm of rectum
C21.0Malignant neoplasm of anus, unspecified
C21.1Malignant neoplasm of anal canal
C21.2Malignant neoplasm of cloacogenic zone
C21.8Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C43.0Malignant melanoma of lip
C43.111Malignant melanoma of right upper eyelid, including canthus
C43.112Malignant melanoma of right lower eyelid, including canthus
C43.121Malignant melanoma of left upper eyelid, including canthus
C43.122Malignant melanoma of left lower eyelid, including canthus
C43.21Malignant melanoma of right ear and external auricular canal
C43.22Malignant melanoma of left ear and external auricular canal
C43.31Malignant melanoma of nose

Procedure codes: 81210.

A54192: Billing and Coding: MolDX: FDA-Approved EGFR Tests (Billing and Coding, effective 2024-05-30)

Covered ICD-10-CM codes
12
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 12 covered ICD-10-CM codes in A54192
ICD-10-CMDescription (FY2027)
C34.00Malignant neoplasm of unspecified main bronchus
C34.01Malignant neoplasm of right main bronchus
C34.02Malignant neoplasm of left main bronchus
C34.11Malignant neoplasm of upper lobe, right bronchus or lung
C34.12Malignant neoplasm of upper lobe, left bronchus or lung
C34.2Malignant neoplasm of middle lobe, bronchus or lung
C34.31Malignant neoplasm of lower lobe, right bronchus or lung
C34.32Malignant neoplasm of lower lobe, left bronchus or lung
C34.81Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82Malignant neoplasm of overlapping sites of left bronchus and lung
C34.91Malignant neoplasm of unspecified part of right bronchus or lung
C34.92Malignant neoplasm of unspecified part of left bronchus or lung

Procedure codes: 81235.

A54194: Billing and Coding: MolDX: MammaPrint (Billing and Coding, effective 2023-11-22)

Covered ICD-10-CM codes
36
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
3
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A54194
ICD-10-CMDescription (FY2027)
C50.011Malignant neoplasm of nipple and areola, right female breast
C50.012Malignant neoplasm of nipple and areola, left female breast
C50.021Malignant neoplasm of nipple and areola, right male breast
C50.022Malignant neoplasm of nipple and areola, left male breast
C50.111Malignant neoplasm of central portion of right female breast
C50.112Malignant neoplasm of central portion of left female breast
C50.121Malignant neoplasm of central portion of right male breast
C50.122Malignant neoplasm of central portion of left male breast
C50.211Malignant neoplasm of upper-inner quadrant of right female breast
C50.212Malignant neoplasm of upper-inner quadrant of left female breast
C50.221Malignant neoplasm of upper-inner quadrant of right male breast
C50.222Malignant neoplasm of upper-inner quadrant of left male breast
C50.311Malignant neoplasm of lower-inner quadrant of right female breast
C50.312Malignant neoplasm of lower-inner quadrant of left female breast
C50.321Malignant neoplasm of lower-inner quadrant of right male breast
C50.322Malignant neoplasm of lower-inner quadrant of left male breast
C50.411Malignant neoplasm of upper-outer quadrant of right female breast
C50.412Malignant neoplasm of upper-outer quadrant of left female breast
C50.421Malignant neoplasm of upper-outer quadrant of right male breast
C50.422Malignant neoplasm of upper-outer quadrant of left male breast
C50.511Malignant neoplasm of lower-outer quadrant of right female breast
C50.512Malignant neoplasm of lower-outer quadrant of left female breast
C50.521Malignant neoplasm of lower-outer quadrant of right male breast
C50.522Malignant neoplasm of lower-outer quadrant of left male breast

Procedure codes: 81479, 81521, 81523.

A54195: Billing and Coding: MolDX: Oncotype DX® Breast Cancer Assay (Billing and Coding, effective 2023-11-22)

Covered ICD-10-CM codes
55
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A54195
ICD-10-CMDescription (FY2027)
C50.011Malignant neoplasm of nipple and areola, right female breast
C50.012Malignant neoplasm of nipple and areola, left female breast
C50.019Malignant neoplasm of nipple and areola, unspecified female breast
C50.021Malignant neoplasm of nipple and areola, right male breast
C50.022Malignant neoplasm of nipple and areola, left male breast
C50.029Malignant neoplasm of nipple and areola, unspecified male breast
C50.111Malignant neoplasm of central portion of right female breast
C50.112Malignant neoplasm of central portion of left female breast
C50.119Malignant neoplasm of central portion of unspecified female breast
C50.121Malignant neoplasm of central portion of right male breast
C50.122Malignant neoplasm of central portion of left male breast
C50.129Malignant neoplasm of central portion of unspecified male breast
C50.211Malignant neoplasm of upper-inner quadrant of right female breast
C50.212Malignant neoplasm of upper-inner quadrant of left female breast
C50.219Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221Malignant neoplasm of upper-inner quadrant of right male breast
C50.222Malignant neoplasm of upper-inner quadrant of left male breast
C50.229Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311Malignant neoplasm of lower-inner quadrant of right female breast
C50.312Malignant neoplasm of lower-inner quadrant of left female breast
C50.319Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321Malignant neoplasm of lower-inner quadrant of right male breast
C50.322Malignant neoplasm of lower-inner quadrant of left male breast
C50.329Malignant neoplasm of lower-inner quadrant of unspecified male breast

Procedure codes: 81519.

A54196: Billing and Coding: MolDX: Oncotype DX® Colon Cancer Assay Update (Billing and Coding, effective 2023-11-22)

Covered ICD-10-CM codes
13
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 13 covered ICD-10-CM codes in A54196
ICD-10-CMDescription (FY2027)
C18.0Malignant neoplasm of cecum
C18.1Malignant neoplasm of appendix
C18.2Malignant neoplasm of ascending colon
C18.3Malignant neoplasm of hepatic flexure
C18.4Malignant neoplasm of transverse colon
C18.5Malignant neoplasm of splenic flexure
C18.6Malignant neoplasm of descending colon
C18.7Malignant neoplasm of sigmoid colon
C18.8Malignant neoplasm of overlapping sites of colon
C18.9Malignant neoplasm of colon, unspecified
C19Malignant neoplasm of rectosigmoid junction
C20Malignant neoplasm of rectum
C21.1Malignant neoplasm of anal canal

Procedure codes: 81525.

A54257: Billing and Coding: MolDX: BluePrint® Test (Billing and Coding, effective 2023-11-16)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record

Procedure codes: 81479.

A54269: Billing and Coding: MolDX: HTTLPR Gene Testing (Billing and Coding, effective 2023-11-22)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record

Procedure codes: 81479.

A54270: Billing and Coding: MolDX: IKBKAP Genetic Testing (Billing and Coding, effective 2023-11-22)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
3
Full article
cms.gov record

Procedure codes: 81260, 81412, 81443.

A54283: Billing and Coding: MolDX: SULT4A1 Genetic Testing (Billing and Coding, effective 2023-11-22)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record

Procedure codes: 81479.

A54295: Billing and Coding: MolDX: PIK3CA Gene Tests (Billing and Coding, effective 2023-11-15)

Covered ICD-10-CM codes
55
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
2
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A54295
ICD-10-CMDescription (FY2027)
C50.011Malignant neoplasm of nipple and areola, right female breast
C50.012Malignant neoplasm of nipple and areola, left female breast
C50.019Malignant neoplasm of nipple and areola, unspecified female breast
C50.021Malignant neoplasm of nipple and areola, right male breast
C50.022Malignant neoplasm of nipple and areola, left male breast
C50.029Malignant neoplasm of nipple and areola, unspecified male breast
C50.111Malignant neoplasm of central portion of right female breast
C50.112Malignant neoplasm of central portion of left female breast
C50.119Malignant neoplasm of central portion of unspecified female breast
C50.121Malignant neoplasm of central portion of right male breast
C50.122Malignant neoplasm of central portion of left male breast
C50.129Malignant neoplasm of central portion of unspecified male breast
C50.211Malignant neoplasm of upper-inner quadrant of right female breast
C50.212Malignant neoplasm of upper-inner quadrant of left female breast
C50.219Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221Malignant neoplasm of upper-inner quadrant of right male breast
C50.222Malignant neoplasm of upper-inner quadrant of left male breast
C50.229Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311Malignant neoplasm of lower-inner quadrant of right female breast
C50.312Malignant neoplasm of lower-inner quadrant of left female breast
C50.319Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321Malignant neoplasm of lower-inner quadrant of right male breast
C50.322Malignant neoplasm of lower-inner quadrant of left male breast
C50.329Malignant neoplasm of lower-inner quadrant of unspecified male breast

Procedure codes: 0155U, 81309.

A54300: Billing and Coding: MolDx: SEPT9 Gene Test (Billing and Coding, effective 2023-11-16)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record

Procedure codes: 81327.

A54688: Billing and Coding: MolDX: FDA-Approved KRAS Tests (Billing and Coding, effective 2023-11-16)

Covered ICD-10-CM codes
37
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
3
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A54688
ICD-10-CMDescription (FY2027)
C77.0Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C77.1Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.2Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.3Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.5Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9Secondary and unspecified malignant neoplasm of lymph node, unspecified
C78.01Secondary malignant neoplasm of right lung
C78.02Secondary malignant neoplasm of left lung
C78.1Secondary malignant neoplasm of mediastinum
C78.2Secondary malignant neoplasm of pleura
C78.39Secondary malignant neoplasm of other respiratory organs
C78.4Secondary malignant neoplasm of small intestine
C78.5Secondary malignant neoplasm of large intestine and rectum
C78.6Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.80Secondary malignant neoplasm of unspecified digestive organ
C78.89Secondary malignant neoplasm of other digestive organs
C79.01Secondary malignant neoplasm of right kidney and renal pelvis
C79.02Secondary malignant neoplasm of left kidney and renal pelvis
C79.11Secondary malignant neoplasm of bladder
C79.19Secondary malignant neoplasm of other urinary organs
C79.2Secondary malignant neoplasm of skin

Procedure codes: 81275, 81276, 81479.

A54830: Billing and Coding: MolDX: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268) (Billing and Coding, effective 2024-04-04)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
5
Full article
cms.gov record

Procedure codes: 81265, 81266, 81267, 81268, 81479.

A55716: Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML) (Billing and Coding, effective 2023-11-16)

Covered ICD-10-CM codes
2
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
2
Full article
cms.gov record
First 2 covered ICD-10-CM codes in A55716
ICD-10-CMDescription (FY2027)
C92.00Acute myeloblastic leukemia, not having achieved remission
C92.02Acute myeloblastic leukemia, in relapse

Procedure codes: 81120, 81121.

A56106: Billing and Coding: MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors (Billing and Coding, effective 2024-01-01)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
3
Full article
cms.gov record

Procedure codes: 81479, 88341, 88342.

A56973: Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (Billing and Coding, effective 2026-07-01)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
656
Full article
cms.gov record

Procedure codes: 0001U, 0004M, 0005U, 0006M, 0007M, 0008U, 0011M, 0012M, 0013M, 0016M, 0016U, 0017M, 0017U, 0018U, 0019U, 0020M, 0022U, 0023U, 0026U, 0027U, 0030U, 0032U, 0034U, 0036U, 0037U, 0040U, 0045U, 0046U, 0047U, 0048U, 0049U, 0050U, 0055U, 0060U, 0069U, 0070U, 0071U, 0072U, 0073U, 0074U and 616 more in the article.

A59646: Billing and Coding: MolDX: Proteomics Testing (Billing and Coding, effective 2026-07-01)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
61
Full article
cms.gov record

Procedure codes: 0002M, 0002U, 0003M, 0003U, 0015M, 0019M, 0021U, 0080U, 0092U, 0095U, 0105U, 0117U, 0166U, 0174U, 0206U, 0207U, 0228U, 0247U, 0249U, 0259U, 0263U, 0295U, 0308U, 0309U, 0310U, 0312U, 0322U, 0344U, 0351U, 0360U, 0365U, 0366U, 0367U, 0375U, 0384U, 0385U, 0387U, 0407U, 0412U, 0415U and 21 more in the article.

Coverage indications, limitations and medical necessity

As of September 16, 2013 CGS Administrators accepts all coverage determinations made by Palmetto GBA through the MolDX Program, which are discussed in the details of this policy.

This coverage policy provides the following information:

• defines tests required to register for a unique identifier

• defines tests required to submit a complete technical assessment (TA) for coverage determination

• defines the payment rules applied to covered tests that are not reported with specific codes

• lists specific covered tests that have completed the registration and TA process and meet Medicare’s reasonable and necessary criteria for coverage

Tests evaluated through the application process and/or technical assessment will be reviewed to answer the following questions:

• Is the test performed in the absence of clinical signs and symptoms of disease?

• Will the test results provide the clinician with information that will improve patient outcomes and/or change physician care and treatment of the patient?

• Will the test results confirm a diagnosis or known information?

• Is the test performed to determine risk for developing a disease or condition?

• Will risk assessment change management of the patient?

• Is there a diagnosis specific indication to perform the test?

• Is the test performed to measure the quality of a process or for Quality Control/Quality Assurance (QC/QA), i.e., a test to ensure a tissue specimen matches the patient?

Molecular Diagnostic Test ( MDT)

MDT: Any test that involves the detection or identification of nucleic acid(s) deoxyribonucleic acid/ribonucleic acid (DNA/RNA), proteins, chromosomes, enzymes, cancer chemotherapy sensitivity and/or other metabolite(s). The test may or may not include multiple components. A MDT may consist of a single mutation analysis/identification, and/or may or may not rely upon an algorithm or other form of data evaluation/derivation.

LDT: Any test developed by a laboratory developed without FDA approval or clearance.

Applicable Tests/Assays

In addition to the MDT definition, this coverage policy applies to all tests that meet at least one of the following descriptions:

• All non-FDA approved/cleared laboratory developed tests (LDT)

• All modified FDA-approved/cleared kits/tests/assays

• All tests/assays billed with more than one code to identify the service, including combinations of method-based, serology-based, and anatomic pathology codes

• All tests that meet the first three bullets and are billed with an NOC code

Unique Test Identifier Requirement

Because the available language in the manuals to describe the pathology and laboratory categories and the tests included in those categories are not specific to the actual test results provided, all MDT services must include an identifier as additional claim documentation. Test providers must apply for an identifier specific to the applicable test and submit the test assigned identifier with the claim for reimbursement. The assigned identifier will provide a crosswalk between the test’s associated detail information on file and the submitted claim detail line(s) required to adjudicate each test’s claim. The unique identifier limits the need to submit the required additional information about the test on each claim.

Technology Assessments (TA)

Molecular Diagnostic Services Program (MolDX ® ) will review all new test/assay clinical information to determine if a test meets Medicare’s reasonable and necessary requirement. Labs must submit a comprehensive dossier on each new test/assay prior to claim submission. MolDX ® will only cover and reimburse tests that demonstrate analytical and clinical validity, and clinical utility at a level that meets the Medicare reasonable and necessary requirement.

Payment Rules

MolDX ® will reimburse:

• approved tests covered for dates of service consistent with the effective date of the coverage determination.

Covered Tests

Please refer to the MolDX ® website www.palmettogba.com/MolDX for covered and excluded tests' specific coding and billing information.

For additional MolDX ® Program information, go to the Medicare home page www.PalmettoGBA.com/MolDX.

MolDX ® expects laboratory providers to follow test indications published by the developer.

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2025-08-21
Last reviewed by the contractor
2025-08-05
MCD version
49

Other related documents: A54901 (Billing and Coding), A59698 (Article), A54584 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L36021 cover?

As of September 16, 2013 CGS Administrators accepts all coverage determinations made by Palmetto GBA through the MolDX Program, which are discussed in the details of this policy. The full 630-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L36021 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L36021?

The companion billing and coding article A54188 lists 253 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L36021?

A denial under LCD L36021 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A54188's 253 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.